Initial Therapeutics
PrivateLast Round
Series A
May 1, 2023
Total Funding Raised
$75M
Company Overview
Initial Therapeutics is a biotechnology company that develops small-molecule medicines designed to prevent pathogenic protein synthesis by selectively terminating translation at the ribosome.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Precision Medicine
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Application
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Initial Therapeutics Comparables
Compare Initial Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Interdict Bio | 89% | |
| Ribometrix | 79% | |
| Arrakis Therapeutics | 78% | |
Initial Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series A | May 1, 2023 |
Initial Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Apple Tree Partners | Series A |
Initial Therapeutics Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Frequently Asked Questions
Common questions about Initial Therapeutics's valuation, stock price, and market status.